Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best upside stocks to invest in now. Earlier on July 23, Revolution Medicines announced that the US FDA granted Breakthrough Therapy Designation to elironrasib (RMC-6291), its RAS(-ON) G12C-selective inhibitor. The designation is for treating adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer/NSCLC who have already undergone chemotherapy and immunotherapy but have not yet been treated with a KRAS G12C inhibitor.
The designation aims to expedite the development and review of the drug, which addresses a significant unmet medical need. It was based on promising data from the Phase 1 RMC-6291-001 clinical trial. In the trial, elironrasib monotherapy showed competitive antitumor activity, a compelling objective response rate, and progression-free survival in patients with advanced KRAS G12C solid tumors.
A researcher poring over test results, illustrating the breakthrough potential of biotechnology.
Elironrasib is an innovative inhibitor that selectively binds to the oncogenic RAS(-ON) form of the RAS G12C variant. This variant is a driver in ~12% of NSCLC cases. Revolution Medicines is currently exploring elironrasib as a monotherapy and in combination with other treatments. KRAS mutations are found in nearly 30% of NSCLC cases, with KRAS G12C being the most common subtype. Currently, there are no fully FDA-approved RAS-targeted inhibitors for patients with KRAS G12C NSCLC.
Revolution Medicines Inc. is a clinical-stage precision oncology company that develops novel targeted therapies for RAS-addicted cancers.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
